secwatch.observer — SEC 8-K summary
======================================

Issuer:     Corbus Pharmaceuticals Holdings, Inc. (CRBP)
CIK:        0001595097
Form:       8-K
Filed at:   2025-05-06T23:59:59+00:00
Accession:  0000950170-25-063990
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Corbus Pharma Q1 net loss $17M; pipeline on track for data in H2 2025
---------------------------------------------------------------------

- Net loss of $17.0M ($1.39/share) vs $6.9M ($0.83) in Q1 2024; operating expenses rose to $19.8M.
- Cash and investments $132.8M; expected to fund operations through Q2 2027.
- CRB-701 Nectin-4 ADC dose optimization ongoing; RP2D expected Q4 2025; FDA Fast Track for cervical cancer.
- CRB-913 CB1 inverse agonist Phase 1 SAD/MAD started March 2025; completion Q3 2025; Phase 1b starts Q4 2025.
- CRB-601 anti-αvβ8 mAb Phase 1 dose escalation ongoing; completion expected Q4 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1595097/000095017025063990/0000950170-25-063990-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1595097/000095017025063990/crbp-20250506.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-063990

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer